Technical Analysis for SNPX - Synaptogenix, Inc.
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Weak or Absent | Down | Down | Down |
Date | Alert Name | Type | % Chg |
---|---|---|---|
Bollinger Band Squeeze | Range Contraction | 0.00% | |
Calm After Storm | Range Contraction | 0.00% | |
Lower Bollinger Band Walk | Weakness | 0.00% | |
BB Squeeze + Lower Band Touch | Range Contraction | 0.00% | |
BB Squeeze Started | Range Contraction | 0.00% | |
Lower Bollinger Band Touch | Weakness | 0.00% | |
Calm After Storm | Range Contraction | 1.22% | |
Lower Bollinger Band Walk | Weakness | 1.22% | |
Inside Day | Range Contraction | 1.22% | |
BB Squeeze Ended | Range Expansion | 1.22% |
Alert | Time |
---|---|
Down 3% | about 9 hours ago |
Fell Below Lower Bollinger Band | about 9 hours ago |
Fell Below Previous Day's Low | about 9 hours ago |
Down 2 % | about 9 hours ago |
Down 1% | about 9 hours ago |
Get this analysis on your stocks daily!
- Earnings date: 02/28/2024
Synaptogenix, Inc. Description
Synaptogenix is a clinical-stage biopharmaceutical company that has historically worked to develop novel therapies for neurodegenerative diseases. Synaptogenix has conducted clinical and preclinical studies of its lead therapeutic candidate, Bryostatin-1, in Alzheimer's disease. Preclinical studies have also demonstrated Bryostatin's regenerative mechanisms of action for the rare disease, Fragile X syndrome, and for other neurodegenerative disorders such as multiple sclerosis, stroke, and traumatic brain injury. The U.S. Food and Drug Administration has granted Orphan Drug Designation to Synaptogenix for Bryostatin-1 as a treatment for Fragile X syndrome. Bryostatin-1 has already undergone testing in more than 1,500 people in cancer studies, thus creating a large safety data base that will further inform clinical trial designs.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Cancer Biology Neuroscience Rare Diseases Alzheimer's Disease Neurodegenerative Diseases Stroke Multiple Sclerosis Amyotrophic Lateral Sclerosis Neurodegeneration Neurodegenerative Disorders Fragile X Syndrome Traumatic Brain Injury
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 47.0 |
52 Week Low | 3.5275 |
Average Volume | 43,858 |
200-Day Moving Average | 5.82 |
50-Day Moving Average | 4.50 |
20-Day Moving Average | 4.29 |
10-Day Moving Average | 4.26 |
Average True Range | 0.30 |
RSI (14) | 42.86 |
ADX | 14.52 |
+DI | 22.04 |
-DI | 19.07 |
Chandelier Exit (Long, 3 ATRs) | 4.14 |
Chandelier Exit (Short, 3 ATRs) | 4.78 |
Upper Bollinger Bands | 4.59 |
Lower Bollinger Band | 3.99 |
Percent B (%b) | 0.27 |
BandWidth | 13.93 |
MACD Line | -0.10 |
MACD Signal Line | -0.09 |
MACD Histogram | -0.0122 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 4.45 | ||||
Resistance 3 (R3) | 4.42 | 4.28 | 4.40 | ||
Resistance 2 (R2) | 4.28 | 4.21 | 4.30 | 4.38 | |
Resistance 1 (R1) | 4.22 | 4.16 | 4.25 | 4.25 | 4.37 |
Pivot Point | 4.08 | 4.08 | 4.10 | 4.10 | 4.08 |
Support 1 (S1) | 4.02 | 4.01 | 4.05 | 4.05 | 3.93 |
Support 2 (S2) | 3.88 | 3.96 | 3.90 | 3.92 | |
Support 3 (S3) | 3.82 | 3.88 | 3.90 | ||
Support 4 (S4) | 3.85 |